Article
Multidisciplinary Sciences
Martina Catalano, Giuseppe Aprile, Raffaele Conca, Roberto Petrioli, Monica Ramello, Giandomenico Roviello
Summary: This study investigated the impact of risk factors such as performance status and comorbidities on the effectiveness of nab-paclitaxel and gemcitabine treatment in patients with metastatic pancreatic cancer. The results showed that patients without risk factors had higher overall survival, and age, performance status, and comorbidities were prognostic factors.
SCIENTIFIC REPORTS
(2022)
Article
Oncology
Pengfei Guo, Tianhong Teng, Wuping Liu, Yanying Fang, Binbin Wei, Jianghua Feng, Heguang Huang
Summary: Pancreatic ductal adenocarcinoma (PDAC) is highly heterogeneous and clinical stages are not associated with metabolic differences. Through serum metabolomic analysis, three metabolic subtypes were identified, with choline-like type showing better long-term prognosis.
INTERNATIONAL JOURNAL OF CANCER
(2022)
Article
Health Care Sciences & Services
Bruna M. M. Rocha, Ross D. Dolan, Carlos E. Paiva, Josh McGovern, Bianca S. R. Paiva, Daniel D. Preto, Donald C. McMillan, Yara C. P. Maia, Barry J. Laird
Summary: This study compares prognostic factors in two international cohorts of patients with advanced cancer and establishes a prognostic framework for treatment. The study finds that despite geographical and socio-demographic differences, similar prognostic factors are associated with long-term survival in both the European and Brazilian cohorts.
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
(2023)
Article
Biochemistry & Molecular Biology
Miguel A. Ortega, Oscar Fraile-Martinez, Leonel Pekarek, Cielo Garcia-Montero, Miguel Angel Alvarez-Mon, Alejandro J. Castellanos, Natalio Garcia-Honduvilla, Julia Bujan, Melchor Alvarez-Mon, Miguel A. Saez, Luis G. Guijarro, Angel Asunsolo
Summary: Pancreatic cancer is a malignancy that is becoming more prevalent, especially in developed countries due to dietary patterns and sedentary lifestyles. It is expected to become the second leading cause of cancer-related deaths in the near future. The low survival rate is attributed to the lack of symptoms in the early stages, leading to metastasis in advanced stages. This study evaluates molecular biomarkers and finds a correlation between their high expression and low survival rate in pancreatic cancer patients.
Article
Oncology
Ryo Saito, Hiromichi Kawaida, Naohiro Hosomura, Hidetake Amemiya, Jun Itakura, Atsushi Yamamoto, Koichi Takiguchi, Suguru Maruyama, Katsutoshi Shoda, Shinji Furuya, Hidenori Akaike, Yoshihiko Kawaguchi, Makoto Sudo, Shingo Inoue, Hiroshi Kono, Daisuke Ichikawa
Summary: This study found that exposure to blood components, particularly platelets and inflammation, can enhance the malignant behaviors of pancreatic cancer cells, leading to poor prognosis for patients.
ANNALS OF SURGICAL ONCOLOGY
(2021)
Article
Oncology
Lingling Lu, Huaxiang Wang, Jian Fang, Jiaolong Zheng, Bang Liu, Lei Xia, Dongliang Li
Summary: OAS1 expression is elevated in pancreatic cancer and is associated with poor prognosis, potentially linked to immune cell abundance.
FRONTIERS IN ONCOLOGY
(2022)
Article
Surgery
Thomas Hank, Ulf Hinz, Thomas Reiner, Giuseppe Malleo, Anna-Katharina Koenig, Laura Maggino, Giovanni Marchegiani, Joerg Kaiser, Salvatore Paiella, Alessandra Binco, Roberto Salvia, Thilo Hackert, Claudio Bassi, Markus W. Buechler, Oliver Strobel
Summary: This study developed and validated a prognostic score for pancreatic cancer based on pretreatment parameters. The score, called HELPP-score, was able to stratify survival independently of resection status and pathological tumor stage.
Article
Oncology
Mingming Zhang, Xiaoru Hu, Ye Kang, Wanfeng Xu, Xianghong Yang
Summary: The study found that fasting blood glucose levels are not significantly associated with overall survival of patients with pancreatic cancer, with only CA199 > 1000 being independently correlated with survival. The median survival in the normal glucose group was 20.5 months, while in the high blood glucose group it was 14.2 months, with no significant difference between the two groups.
Article
Cell Biology
Feng Zhang, Wenhui Zhong, Honghao Li, Kaijun Huang, Min Yu, Yubin Liu
Summary: TP53 mutation is a critical driver mutation in pancreatic cancer, and a prognostic TP53-associated signature based on differentially expressed genes has been developed and validated in multiple patient cohorts. Patients in the low-risk group of the signature have better prognosis and lower immune activity, while those in the high-risk group show poor survival and enhanced response to certain chemotherapeutic agents. Overall, the TP53-associated signature is a novel prognostic biomarker and predictive indicator of pancreatic cancer.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Article
Multidisciplinary Sciences
Le Wang, Ping Luo, Zhiwen Yang, Xiaoming Zhong, Changxue Ji
Summary: FOXP1 overexpression is associated with a higher survival rate in pancreatic cancer patients. High expression of FOXP1 inhibits pancreatic cancer growth, while low expression of FOXP1 promotes tumorigenesis. FOXP1 suppresses pancreatic cancer growth via an IRF1-dependent pathway and could serve as a potential prognostic biomarker for pancreatic cancer patients.
Article
Biotechnology & Applied Microbiology
Xuechen Ren, Chengliang Zhou, Yu Lu, Fulin Ma, Yong Fan, Chen Wang
Summary: This study utilized single-cell RNA sequencing to reveal the invasive trajectory of ductal cells in PDAC and identified crucial CRGs, which can help predict patient survival and provide potential clinical therapeutic targets.
Article
Oncology
J. Keyl, S. Kasper, M. Wiesweg, J. Goetze, M. Schoenrock, M. Sinn, A. Berger, E. Nasca, K. Kostbade, B. Schumacher, P. Markus, D. Albers, J. Treckmann, K. W. Schmid, H-U Schildhaus, J. T. Siveke, M. Schuler, J. Kleesiek
Summary: In this study, a random survival forest model was built using clinical data of patients with advanced PDAC to predict prognosis. The results showed that this approach outperformed existing scoring systems in identifying high- and low-risk subgroups. The inclusion of KRAS p.G12D mutation status further improved the prediction, while radiomics data of the primary tumor had little impact on the results.
Review
Oncology
Xiaoyang Lan, Gabrielle Robin, Jessica Kasnik, Grace Wong, Omar Abdel-Rahman
Summary: Pancreatic ductal carcinomas (PDACs) are difficult to diagnose early and have a poor prognosis. Many PDAC patients suffer from nutritional deficiencies related to their cancer. Pancreatic enzyme insufficiency (PEI) is a common cause of malnutrition in PDAC. This paper reviews past studies on malnutrition in PDAC, focusing on PEI and its treatment, and highlights knowledge gaps among healthcare professionals regarding PEI.
Article
Oncology
Bartlomiej Barczynski, Karolina Fraszczak, Artur Wnorowski, Jan Kotarski
Summary: Endometrial cancer is a leading cause of female genital tract malignancies, and our study assesses the influence of clinicopathological features on overall survival. We found that menopause status and related characteristics strongly correlate with patients' survival. Further research is needed to improve personalized care for cancer patients.
Article
Oncology
Taisuke Imamura, Yukiyasu Okamura, Teiichi Sugiura, Takaaki Ito, Yusuke Yamamoto, Ryo Ashida, Katsuhisa Ohgi, Shimpei Otsuka, Katsuhiko Uesaka
Summary: The study revealed that ALBI grade is a clinically useful predictor for prognosis in pancreatic cancer patients, with high ALBI grade being associated with worse survival outcomes.
ANNALS OF SURGICAL ONCOLOGY
(2021)